Matinas BioPharma Holdings Inc. (AMEX:MTNB) finished Wednesday with an addition of $0.02 to close at $1.17, an upside of 1.74 percent. An average of 2,131,660 shares of common stock have been traded in the last five days. There was a gain of $0.1200 in the past week. The last 20 days have seen an average of 3,598,100 shares traded, while the 50-day average volume stands at 2,631,810.
MTNB stock has decreased by -0.85% in the last month. The company shares reached their 1-month lowest point of $1.0200 on 09/15/21. With the stock rallying to its 52-week high on 01/05/21, shares of the company touched a low of $0.67 and a high of $2.22 in 52 weeks. In spite of this, the price is down -47.30% from the 52-week high.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Matinas BioPharma Holdings Inc. (MTNB) has a trailing price-to-earnings (P/E) ratio of 34.65 for the broader industry and 32.30 for the sector. The stock’s beta is 2.33. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 1279.80, the price-to-book (PB) ratio at 3.77.
The quick ratio of Matinas BioPharma Holdings Inc. for the three months ended June 29 was 17.00, and the current ratio was 17.00, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending June 29. Matinas BioPharma Holdings Inc.’s EBITDA margin for the year ending June 29 is -14799.16%. Its gross profit as reported stood at $24.36 million compared to revenue of $0.16 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Matinas BioPharma Holdings Inc.’s return on assets was -31.10%, compared to -156.8% over the last five years. Meanwhile, the return on equity (ROE) for the past 12 months has been -35.80% and the 5-year average holds at -414.2%. For the broader industry, ROE averaged -68.79 over the past year.
For the three-month period that ended June 29, Matinas BioPharma Holdings Inc. had $29.49 million in cash. The analyst consensus anticipated Matinas BioPharma Holdings Inc.’s latest quarter earnings to come in at -$0.03 per share, but it turned out to be -$0.02, a 33.30% surprise. For the quarter, EBITDA amounted to -$4.55 million. Shareholders own equity worth $214.74 million.
From a technical analysis perspective, let’s take a brief look at Matinas BioPharma Holdings Inc. (MTNB) price momentum. RSI 9-day as of the close on 13 October was 52.28%, suggesting the stock is Neutral, with historical volatility in this time frame at 85.66%.
As of today, MTNB’s price is $1.1240 +11.43% or $0.1200 from its 5-day moving average. MTNB is currently trading +7.34% higher than its 20-day SMA and +41.01% higher than its 100-day SMA. However, the stock’s current price level is +60.25% above the SMA50 and +32.95% above the SMA200.
The stochastic %K and %D were 22.41% and 16.50%, respectively, and the average true range (ATR) was 0.1216. With the 14-day stochastic at 24.14% and the average true range at 0.1177, the RSI (14) stands at 54.10%. The stock has reached 0.0411 on the 9-day MACD Oscillator while the 14-day reading was at -0.0571.
Piper Sandler downgraded Matinas BioPharma Holdings Inc. (AMEX: MTNB) to a a Neutral rating in its most recent analyst report. Previously, the stock was rated as a an Overweight.The consensus rating for Matinas BioPharma Holdings Inc. (MTNB) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell MTNB, while 1 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 4 others rate it as a “buy”.
What is MTNB’s price target for the next 12 months?
Analysts predict a range of price targets between $0.90 and $3.00, with a median target of $3.00. Taking a look at these predictions, the average price target given by analysts for Matinas BioPharma Holdings Inc. (MTNB) stock is $2.38.